Document 2793
 DOCN  M94A2793
 TI    Pharmacokinetics of GM-CSF and early leucocyte response after
       subcutaneous (SC) GM-CSF administration to AIDS patients.
 DT    9412
 AU    Henrivaux P; Fairon Y; C. H. St Joseph-Esperance, Liege, Belgium.
 SO    Int Conf AIDS. 1994 Aug 7-12;10(1):223 (abstract no. PB0321). Unique
       Identifier : AIDSLINE ICA10/94369782
 AB    INTRODUCTION. Our study aimed to assess the pharmacokinetic profile of
       sc GM-CSF (Leucomax, Schering-Plough) in AIDS patients, to verify the
       efficacy of low doses of GM-CSF in AIDS patients and to verify the rapid
       leucocyte response that we suspected from our clinical experience.
       METHODS: Low doses of GM-CSF (mean +/- sem: 1.16 +/- 0.06 microgram/kg)
       were sc administered to 8 AIDS patients. Serum GM-CSF levels were
       determined by an immunoenzyme assay (Medgenix Diagnostics). Leucocyte
       counts and GM-CSF levels were determined at 0, 1, 3, 5, 7, 9, and 11
       hours. RESULTS: GM-CSF serum levels reached peak values of 641 +/- 109
       pg/ml at 3 hour. Leucocyte response is characterized by an initial drop
       (due to the decrease of neutrophils) at 1 hour followed by an increase
       reaching maximal value at 8-12 hour. CONCLUSIONS. Despite leucopenia,
       basal GM-CSF is low in AIDS patients. Subcutaneous GM-CSF resorption is
       not altered in AIDS patients. To our knowledge, our study is the first
       one to describe that leucocyte response after GM-CSF to AIDS presents a
       comparable profile to that observed in healthy subjects.
 DE    Acquired Immunodeficiency Syndrome/*THERAPY  Biological Response
       Modifiers/ADMINISTRATION & DOSAGE/  *PHARMACOKINETICS/THERAPEUTIC USE
       Drug Evaluation  Granulocyte-Macrophage Colony-Stimulating
       Factor/ADMINISTRATION &  DOSAGE/*PHARMACOKINETICS/THERAPEUTIC USE  Human
       Injections, Subcutaneous  Leukocyte Count/*DRUG EFFECTS  MEETING
       ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).